FGF21 analogs therefore represent a promising emerging class of NASH therapeutics, as a number of them have demonstrated pleiotropic effects consistent with improved liver health and whole-body metabolism. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.